Sanofi India Limited Stock NSE India S.E.

Equities

SANOFI

INE058A01010

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:49 2024-04-19 am EDT 5-day change 1st Jan Change
8,259 INR -2.70% Intraday chart for Sanofi India Limited -2.27% +2.37%
Sales 2023 28.51B 342M Sales 2024 * 30.46B 365M Capitalization 190B 2.28B
Net income 2023 6.03B 72.28M Net income 2024 * 6.48B 77.62M EV / Sales 2023 6.52 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 6.24 x
P/E ratio 2023
30.8 x
P/E ratio 2024 *
29.3 x
Employees 2,651
Yield 2023 *
4.2%
Yield 2024 *
2.19%
Free-Float 39.42%
More Fundamentals * Assessed data
Dynamic Chart
Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility CI
Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee CI
Cipla to Distribute Sanofi's CNS Product Line in India MT
Sanofi India Limited, Sanofi Healthcare India Private Limited and Cipla Limited Announce an Exclusive Partnership CI
Sanofi India Limited and Emcure Pharmaceuticals Announces Exclusive Distribution Partnership to Broad Broadline Reach of Sanofi's Cardiovascular Brands CI
Transcript : Sanofi India Limited, Q4 2023 Earnings Call, Feb 26, 2024
Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024 CI
Sanofi India Limited Declares Interim Dividend for the Financial Year Ended 31St December, 2023, Payable on or After 20 March, 2024 CI
Sanofi India Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sanofi India Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024 CI
Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa DJ
Trending : Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials DJ
Transcript : Sanofi India Limited, Q3 2023 Earnings Call, Nov 15, 2023
Sanofi India's CFO Steps Down MT
More news
1 day-2.70%
1 week-2.27%
Current month+1.79%
1 month+5.75%
3 months-1.91%
6 months+10.67%
Current year+2.37%
More quotes
1 week
8 232.20
Extreme 8232.2
8 618.00
1 month
7 505.00
Extreme 7505
8 839.00
Current year
7 505.00
Extreme 7505
9 380.00
1 year
5 400.00
Extreme 5400
9 380.00
3 years
5 202.10
Extreme 5202.1
9 380.00
5 years
5 202.10
Extreme 5202.1
9 380.00
10 years
2 761.10
Extreme 2761.1
9 380.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-05-31
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 74 16-04-29
Chairman 72 16-04-29
Director/Board Member 66 20-07-28
More insiders
Date Price Change Volume
24-04-19 8,259 -2.70% 13 179
24-04-18 8,488 +1.06% 20,864
24-04-16 8,399 -1.25% 19,063
24-04-15 8,505 +0.44% 19,820
24-04-12 8,468 +0.21% 14,135

Delayed Quote NSE India S.E., April 19, 2024 at 07:43 am EDT

More quotes
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise